PharmGen Science팜젠사이언스
004720 · KOSPI · ₩004720 · 팜젠사이언스
₩2,765▲ ₩15 (0.55%)End-of-day · Oct 30, 2026 · End-of-day prices.
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | ₩173B | ₩171B | ₩167B | ₩151B | ₩110B |
| Cost of sales | ₩61B | ₩63B | ₩69B | ₩70B | ₩49B |
| Gross profit | ₩112B | ₩108B | ₩98B | ₩81B | ₩61B |
| Operating income | ₩6B | ₩11B | ₩9.1B | ₩7.5B | −₩4.9B |
| Net income | −₩117B | ₩7B | ₩16B | ₩1.2B | −₩4.2B |
| Net income to shareholders | −₩117B | ₩7B | ₩16B | ₩1.2B | −₩4.2B |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Total assets | ₩195B | ₩203B | ₩192B | ₩168B | ₩163B |
| Current assets | ₩96B | ₩111B | ₩95B | ₩70B | ₩77B |
| Cash and equivalents | ₩22B | ₩38B | ₩37B | ₩19B | ₩34B |
| Total liabilities | ₩49B | ₩83B | ₩79B | ₩82B | ₩86B |
| Current liabilities | ₩34B | ₩65B | ₩63B | ₩68B | ₩71B |
| Borrowings | ₩5.5B | ₩38B | ₩37B | ₩39B | ₩47B |
| Total equity | ₩146B | ₩120B | ₩114B | ₩86B | ₩78B |
| Shareholders' equity | ₩146B | ₩120B | ₩114B | ₩86B | ₩78B |
Cash flow
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash from operations | ₩5.3B | ₩2.4B | ₩13B | −₩1.3B | ₩7.9B |
| Capital spending | ₩1.5B | ₩919M | ₩2.3B | ₩9.9B | ₩31B |
| Free cash flow | ₩3.9B | ₩1.5B | ₩11B | −₩11B | −₩23B |
Consolidated where available. Amounts in won.
Also known as: PharmGen Science / 팜젠사이언스 / 004720 / KRX:004720
Source: KRX statistical information